📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
0 analysed today
FollowTelegram
0
Today
152,139
All-time analysed
43,645
Positive
6,747
Negative
92,898
Neutral
8,781
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
54 announcements match the current filters (relevance ≥ 5).
Alkem Laboratories to Outline MedTech Strategic Roadmap on February 18, 2026
Alkem Laboratories has scheduled an investor meet for February 18, 2026, to specifically discuss the strategic direction of its MedTech division. The meeting will feature senior leadership from both the parent company and Alkem MedTech to present the 'strategic way forward.' This event is significant as it indicates a focused effort to scale the medical technology business, which could diversify the company's traditional pharmaceutical revenue base. Investors should monitor the session for details on product pipelines, market entry strategies, and capital expenditure plans for this segment.
Key Highlights
Investor meet scheduled for February 18, 2026, at 4:30 PM IST in Mumbai.
The primary agenda is to outline Alkem MedTech’s strategic roadmap and future growth plans.
Senior leadership from both Alkem Laboratories and Alkem MedTech will be present to interact with institutional investors.
The session aims to highlight the company's focus on innovative, affordable, and accessible medical technology solutions.
👀 What to Watch
Investors should track the post-meet presentation or transcript to understand the scale of Alkem's MedTech ambitions and its projected contribution to the bottom line. This segment could be a long-term value unlock if the strategy demonstrates a clear path to high-margin growth.
Alkem MedTech to Acquire 55% Stake in Switzerland's Occlutech for INR 1,074 Crore
Alkem Laboratories' subsidiary, Alkem MedTech, has announced a binding offer to acquire a 55% majority stake in Swiss-based Occlutech Holding AG for approximately INR 1,074 crore (EUR 99.4 million). Occlutech is a leading global player in minimally invasive cardiac implants, ranking second in Europe and third globally. The company reported 2025 revenues of EUR 49.4 million with a 15.7% CAGR over the last three years, primarily from European and US markets. This acquisition marks Alkem's strategic entry into the high-barrier cardiovascular devices segment and significantly expands its global medical technology footprint.
Key Highlights
Acquisition of up to 55% stake in Occlutech Holding AG for EUR 99.4 million (approx. INR 1,074 crore)
Occlutech is the 2nd largest company in Europe and 3rd globally in minimally invasive cardiac implants
Target company recorded revenue of EUR 49.4 million in 2025 with a 15.7% CAGR over three years
Provides immediate access to high-value regulated markets including the US, Japan, and Germany
Transaction is expected to be completed by June 2026 subject to regulatory approvals
👀 What to Watch
Investors should view this as a significant long-term growth driver that diversifies Alkem's revenue stream into high-margin medical technology. Monitor the progress of regulatory approvals and the subsequent integration of Occlutech's R&D capabilities.
Alkem Q3 FY26 Revenue Grows 11% to ₹37,368 Mn; Announces Strategic Occlutech Acquisition
Alkem Laboratories reported a steady Q3 FY26 with 10.7% YoY revenue growth, driven by a robust 26.6% surge in international markets. While domestic growth was moderate at 5.5%, the company outperformed the market in key acute and chronic segments. A major strategic highlight is the planned acquisition of a majority stake in Swiss-based Occlutech to expand into the global MedTech space. Profit growth was slightly muted at 1.6% due to a ₹528 million exceptional charge related to new labour codes.
Key Highlights
Total revenue grew 10.7% YoY to ₹37,368 million, with EBITDA margins remaining stable at 22.2%.
International business led growth with US sales up 18.8% and Non-US sales jumping 41.6% YoY.
Strategic entry into MedTech via acquisition of Occlutech, the world's third-largest player in cardiac implants.
Outperformed Indian Pharmaceutical Market (IPM) in acute (80 bps) and chronic (18 bps) segments.
Upcoming launch of GLP-1 semaglutide in March 2026 identified as a key future growth driver.
👀 What to Watch
Investors should view the strong international growth and the strategic pivot into MedTech as long-term positives. Monitor the integration of Occlutech and the market reception of the GLP-1 launch in March 2026.
Alkem Labs Approves Amendment for Saudi Arabia JV; Retains 51% Controlling Stake
Alkem Laboratories has updated its Joint Venture (JV) plans in Saudi Arabia by amending the Shareholders' Agreement. The company will maintain a 51% majority stake in the new subsidiary, while the 49% partner stake will now be held by Vitals Biotech Company instead of an individual partner. This administrative change facilitates the company's strategic entry into the Middle Eastern pharmaceutical market. The board's approval on February 13, 2026, signals continued progress on this international expansion initiative.
Key Highlights
Alkem Laboratories to hold a 51% majority stake in the Saudi Arabian Joint Venture.
JV partner stake of 49% transferred from Mr. Abdulaziz Alsheikh to his wholly-owned firm, Vitals Biotech Company.
Board of Directors approved the amendment to the Shareholders' Agreement on February 13, 2026.
The JV follows an initial agreement executed on August 12, 2025, for expansion into the Kingdom of Saudi Arabia.
👀 What to Watch
Investors should monitor the progress of this JV as it represents a key geographical diversification into the GCC region. No immediate action is required as this is an administrative update to a previously announced expansion plan.
Alkem Subsidiary Enzene Biosciences to Raise ₹26.16 Crore via Series B CCPS
Alkem Laboratories' subsidiary, Enzene Biosciences, has entered into an amendment agreement to raise approximately ₹26.16 crore through a private placement. The funding involves the issuance of 5,58,302 Series B Compulsorily Convertible Preference Shares (CCPS) and 10 equity shares to F-Prime Capital and ERVI Healthcare. Post-transaction, Alkem will maintain a majority stake of 88.99% in Enzene on a fully diluted basis. This capital infusion by specialized healthcare investors validates the growth potential of Alkem's biotech arm.
Key Highlights
Enzene Biosciences to receive an aggregate infusion of ₹26,16,25,003 from F-Prime and ERVI Healthcare
Securities issued at ₹468.60 per share, including a significant premium of ₹458.60 per share
Alkem Laboratories' shareholding in Enzene will be 88.99% post-allotment on a fully diluted basis
New investors F-Prime and ERVI Healthcare will hold 1.87% and 0.71% respectively
The agreement amends the existing Shareholders' Agreement to include ERVI Healthcare as a party
👀 What to Watch
Investors should monitor the growth of Enzene Biosciences as it attracts external capital at a premium, which could lead to future value unlocking for Alkem. The continued majority stake ensures Alkem remains the primary beneficiary of the subsidiary's potential success in the biologics space.
Alkem Laboratories to Merge Wholly-Owned Subsidiary Adroit Biomed with Itself
The Board of Alkem Laboratories has approved the amalgamation of its wholly-owned subsidiary, Adroit Biomed Limited (ABL), into the parent company. ABL, which operates in the pharmaceutical, cosmetic, and nutraceutical trading space, reported a revenue of INR 596.8 million for FY25. As ABL is a 100% subsidiary, no new shares will be issued, and the shareholding pattern of Alkem remains unchanged. The merger is intended to streamline the corporate structure, reduce administrative overheads, and consolidate intellectual property assets.
Key Highlights
Adroit Biomed Limited (ABL) to merge into Alkem Laboratories via a scheme of arrangement.
ABL reported FY25 revenue of INR 596.8 million and a net worth of INR 75.7 million.
No cash consideration or share issuance involved as ABL is a 100% subsidiary of Alkem.
The merger aims to integrate business operations and achieve significant reduction in administrative and managerial overheads.
The scheme is subject to approval from the NCLT Mumbai bench and other regulatory authorities.
👀 What to Watch
This is an internal restructuring aimed at operational efficiency and does not change the fundamental value or shareholding of the company. Investors should treat this as a routine corporate simplification move.
Alkem Laboratories Declares ₹43 Interim Dividend; Q3 Net Profit Rises to ₹6,360 Million
Alkem Laboratories has declared a substantial interim dividend of ₹43 per share for FY 2025-26, with the record date set for February 20, 2026. The company reported a 10.7% year-on-year increase in consolidated revenue from operations, reaching ₹37,368.2 million for Q3 FY26. Despite an exceptional loss of ₹527.9 million during the quarter, net profit attributable to owners grew to ₹6,360.2 million from ₹6,258.2 million in the previous year. For the nine-month period, the company showed strong performance with net profit rising to ₹20,653.4 million compared to ₹18,596.2 million in the prior year.
Key Highlights
Declared an interim dividend of ₹43 per equity share (2150% of face value).
Consolidated Revenue from Operations grew 10.7% YoY to ₹37,368.2 million in Q3 FY26.
Net Profit attributable to owners increased to ₹6,360.2 million for the quarter.
Nine-month (9M FY26) Net Profit rose to ₹20,653.4 million from ₹18,596.2 million YoY.
Dividend record date is February 20, 2026, with payment starting March 6, 2026.
👀 What to Watch
Investors should ensure they hold shares by the record date of February 20 to qualify for the ₹43 dividend. The steady revenue growth and healthy dividend payout reflect strong cash flows and operational stability.
Alkem Labs Declares Rs 43 Interim Dividend; Q3 Net Profit Rises to Rs 6,360 Million
Alkem Laboratories has declared a substantial interim dividend of Rs. 43 per equity share for the financial year 2025-2026, with the record date fixed as February 20, 2026. The company reported a consolidated revenue of Rs. 37,368.2 million for Q3 FY26, up from Rs. 33,742.8 million in the same quarter last year. Net profit attributable to owners for the quarter stood at Rs. 6,360.2 million, reflecting steady growth. Dividend payments are scheduled to commence from March 6, 2026.
Key Highlights
Declared an interim dividend of Rs. 43 per equity share (2150% of face value).
Consolidated Q3 FY26 revenue grew to Rs. 37,368.2 million from Rs. 33,742.8 million YoY.
Net profit for the quarter attributable to owners reached Rs. 6,360.2 million.
Record date for dividend eligibility is February 20, 2026, with payment starting March 6, 2026.
Nine-month (9M FY26) revenue increased to Rs. 111,089.5 million compared to Rs. 98,207.7 million YoY.
👀 What to Watch
Investors interested in the dividend payout should ensure they hold the stock before the record date of February 20, 2026. The consistent revenue growth and strong dividend yield make it a positive signal for long-term shareholders.
Alkem Labs Q3 Profit Up 1.9% YoY to ₹653 Cr; Declares ₹43 Interim Dividend
Alkem Laboratories reported a 10.7% YoY increase in consolidated revenue to ₹37,368.2 million for the quarter ended December 31, 2025. Net profit grew modestly by 1.9% YoY to ₹6,530.3 million, impacted by an exceptional loss of ₹527.9 million during the quarter. A significant highlight for shareholders is the declaration of a substantial interim dividend of ₹43 per share. While YoY performance remains positive, the company experienced a sequential decline in both revenue and profit compared to Q2 FY26.
Key Highlights
Consolidated Revenue from Operations rose 10.7% YoY to ₹37,368.2 million in Q3 FY26.
Net Profit after tax stood at ₹6,530.3 million, a slight increase from ₹6,407.9 million in Q3 FY25.
Declared an interim dividend of ₹43 per equity share (2150% of face value) with a record date of Feb 20, 2026.
Nine-month FY26 revenue reached ₹111,089.5 million, representing a 13.1% growth over the previous year.
Exceptional items of ₹527.9 million were recorded in the current quarter, impacting the bottom line.
👀 What to Watch
The modest profit growth and sequential decline suggest margin pressure, but the high interim dividend provides immediate value to shareholders. Investors should monitor the impact of exceptional items and the company's growth trajectory in its core pharmaceutical segments.
Alkem Labs Declares ₹43 Interim Dividend; Q3 Revenue Grows 10.7% YoY
Alkem Laboratories has declared a substantial interim dividend of ₹43 per equity share for FY 2025-26, with the record date set for February 20, 2026. The company reported a consolidated revenue of ₹37,368.2 million for Q3 FY26, marking a 10.7% growth compared to the same quarter last year. Net profit attributable to owners rose slightly to ₹6,360.2 million from ₹6,258.2 million YoY, despite being weighed down by an exceptional loss of ₹527.9 million. For the nine-month period ended December 2025, the company's profit reached ₹20,653.4 million, showing a healthy 11% growth over the previous year.
Key Highlights
Declared an interim dividend of ₹43 per equity share on a face value of ₹2.
Q3 FY26 Revenue from Operations increased 10.7% YoY to ₹37,368.2 million.
Nine-month (9M FY26) Revenue reached ₹111,089.5 million compared to ₹98,207.7 million in 9M FY25.
Net Profit for the quarter stood at ₹6,360.2 million after accounting for an exceptional loss of ₹527.9 million.
The record date for dividend eligibility is February 20, 2026, with payment starting March 6, 2026.
👀 What to Watch
Investors should ensure they hold shares by the February 20 record date to qualify for the ₹43 dividend. The steady revenue growth and strong 9-month performance indicate solid fundamentals, making it a positive hold for long-term investors.
Alkem Labs Completes Trade Generics Business Transfer for Total Consideration of Rs 532.5 Cr
Alkem Laboratories has finalized the transfer of its trade generics business to its wholly-owned subsidiary, Alkem Wellness Limited. The transaction was conducted as a slump sale on a going concern basis, effective from October 1, 2025. The company received the final balance payment of Rs 32.5 crores on December 30, 2025, bringing the total aggregate sale consideration to Rs 532.5 crores. This internal restructuring is now complete following the terms of the Business Transfer Agreement signed in September 2025.
Key Highlights
Final balance consideration of Rs 32.5 crores received on December 30, 2025
Total aggregate sale consideration for the trade generics business reached Rs 532.5 crores
Business transferred to Alkem Wellness Limited, a 100% wholly-owned subsidiary
Transaction executed as a slump sale on a going concern basis effective October 1, 2025
👀 What to Watch
As this is an internal transfer to a 100% subsidiary, there is no impact on consolidated financials; investors should focus on whether this restructuring improves operational efficiency in the generics segment.
Alkem Labs Invests Rs 300 Crore in Subsidiary Enzene Biosciences via Rights Issue
Alkem Laboratories has infused approximately Rs 300 crore into its subsidiary, Enzene Biosciences, by subscribing to a rights issue. The company acquired 64.02 lakh equity shares at a price of Rs 468.60 per share, increasing its total stake in the subsidiary to 99.61%. The capital is intended to fund Enzene's capital expenditure and working capital requirements for its biosimilars and biologics business. Enzene has demonstrated strong growth, with its turnover rising from Rs 144 crore in FY23 to Rs 363.62 crore in FY25.
Key Highlights
Total investment of Rs 299.99 crore in Enzene Biosciences Limited.
Acquisition of 64,02,018 equity shares at an issue price of Rs 468.60 per share.
Enzene's revenue grew significantly from Rs 144 crore in FY23 to Rs 363.62 crore in FY25.
Post-allotment, Alkem Laboratories holds a 99.61% stake in the subsidiary.
Funds will be utilized for capex and working capital in the high-growth biosimilars and CDMO segment.
👀 What to Watch
Investors should monitor the scaling of Enzene as it represents Alkem's foray into the high-potential biologics and CDMO space. The consistent revenue growth in the subsidiary is a positive sign for long-term value creation.
Alkem's Daman facility inspected by Malta Medicines Authority
Alkem Laboratories announced that its manufacturing facility in Daman, India, was inspected by the Malta Medicines Authority from December 5th to December 9th, 2025. The inspection concluded with no critical observations, three major observations, and a few minor observations. Alkem plans to address these observations within the stipulated timeframe. This regulatory update indicates ongoing scrutiny of manufacturing standards.
Key Highlights
GMP inspection by Malta Medicines Authority conducted from 05th December, 2025 to 09th December, 2025
Inspection concluded on 09th December, 2025
The inspection resulted in three major observations
The inspection resulted in a few minor observations
👀 What to Watch
Investors should monitor Alkem's progress in addressing the observations made by the Malta Medicines Authority. Any failure to resolve these issues could potentially impact future regulatory approvals and, consequently, the company's operations.
Alkem Labs Receives GST Order for ₹27.15 Lakh Plus Penalty
Alkem Laboratories has received an order from the Assistant Commissioner, Central Goods & Service Tax Division, Dehradun, demanding GST of ₹27,14,603 for the period from FY2018-2019 to 2022-2023. The order also includes a penalty of ₹27,79,266 and applicable interest. The company intends to appeal the order, as it disagrees with the demand, which mainly alleges excess availment of ITC. Alkem Labs believes there will be no material impact on its financial or operational activities.
Key Highlights
GST demand of ₹27,14,603 for FY2018-2019 to 2022-2023
Penalty of ₹27,79,266 imposed
Order received on 03rd December 2025
Demand order alleges excess availment of ITC
👀 What to Watch
Investors should monitor Alkem Labs' appeal process regarding the GST order. While the company anticipates no material impact, any significant developments in the case could affect investor sentiment.
